We thus hypothesized that effective treatment of brain cancer with immunotherapy should involve the activation of brain local immune system by drugs able to reach the brain tumor by crossing the BBB, which cannot be readily achieved by free checkpoint inhibitor antibodies including a-CTLA-4 and a-PD-1 with clinically relevant I.V. administration. The gene discussed is CTLA4; the disease is brain cancer.